Differential durability of immune responses to measles and mumps following MMR vaccination

Richard B Kennedy, Inna G. Ovsyannikova, Antonia Thomas, Beth R. Larrabee, Steven Rubin, Gregory A. Poland

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II® vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.

Original languageEnglish (US)
Pages (from-to)1775-1784
Number of pages10
JournalVaccine
Volume37
Issue number13
DOIs
StatePublished - Mar 22 2019

Fingerprint

Mumps
Measles
durability
Vaccination
immunity
vaccination
immune response
vaccines
neutralizing antibodies
neutralization
Immunity
incidence
pathogens
Mumps Vaccine
dosage
Neutralizing Antibodies
Disease Outbreaks
Vaccines
Immunoglobulin G

Keywords

  • Antibodies
  • Cell-mediated immunity
  • Humoral immunity
  • Measles
  • Measles vaccine
  • Measles virus
  • MMR-II vaccine
  • Mumps
  • Mumps vaccine
  • Mumps virus
  • T cell ELISPOT

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Kennedy, R. B., Ovsyannikova, I. G., Thomas, A., Larrabee, B. R., Rubin, S., & Poland, G. A. (2019). Differential durability of immune responses to measles and mumps following MMR vaccination. Vaccine, 37(13), 1775-1784. https://doi.org/10.1016/j.vaccine.2019.02.030

Differential durability of immune responses to measles and mumps following MMR vaccination. / Kennedy, Richard B; Ovsyannikova, Inna G.; Thomas, Antonia; Larrabee, Beth R.; Rubin, Steven; Poland, Gregory A.

In: Vaccine, Vol. 37, No. 13, 22.03.2019, p. 1775-1784.

Research output: Contribution to journalArticle

Kennedy, RB, Ovsyannikova, IG, Thomas, A, Larrabee, BR, Rubin, S & Poland, GA 2019, 'Differential durability of immune responses to measles and mumps following MMR vaccination', Vaccine, vol. 37, no. 13, pp. 1775-1784. https://doi.org/10.1016/j.vaccine.2019.02.030
Kennedy, Richard B ; Ovsyannikova, Inna G. ; Thomas, Antonia ; Larrabee, Beth R. ; Rubin, Steven ; Poland, Gregory A. / Differential durability of immune responses to measles and mumps following MMR vaccination. In: Vaccine. 2019 ; Vol. 37, No. 13. pp. 1775-1784.
@article{284184f800634bcfb7ea46146223a11f,
title = "Differential durability of immune responses to measles and mumps following MMR vaccination",
abstract = "The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II{\circledR} vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.",
keywords = "Antibodies, Cell-mediated immunity, Humoral immunity, Measles, Measles vaccine, Measles virus, MMR-II vaccine, Mumps, Mumps vaccine, Mumps virus, T cell ELISPOT",
author = "Kennedy, {Richard B} and Ovsyannikova, {Inna G.} and Antonia Thomas and Larrabee, {Beth R.} and Steven Rubin and Poland, {Gregory A.}",
year = "2019",
month = "3",
day = "22",
doi = "10.1016/j.vaccine.2019.02.030",
language = "English (US)",
volume = "37",
pages = "1775--1784",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "13",

}

TY - JOUR

T1 - Differential durability of immune responses to measles and mumps following MMR vaccination

AU - Kennedy, Richard B

AU - Ovsyannikova, Inna G.

AU - Thomas, Antonia

AU - Larrabee, Beth R.

AU - Rubin, Steven

AU - Poland, Gregory A.

PY - 2019/3/22

Y1 - 2019/3/22

N2 - The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II® vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.

AB - The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II® vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.

KW - Antibodies

KW - Cell-mediated immunity

KW - Humoral immunity

KW - Measles

KW - Measles vaccine

KW - Measles virus

KW - MMR-II vaccine

KW - Mumps

KW - Mumps vaccine

KW - Mumps virus

KW - T cell ELISPOT

UR - http://www.scopus.com/inward/record.url?scp=85061647595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061647595&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2019.02.030

DO - 10.1016/j.vaccine.2019.02.030

M3 - Article

C2 - 30797639

AN - SCOPUS:85061647595

VL - 37

SP - 1775

EP - 1784

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 13

ER -